7 results
Clostridium Dificile Risk by Antibiotic Class

Pooled and study-specific risk estimates of community-associated CDI risk by antibiotic
Clostridium Dificile ... Risk by Antibiotic ... #CDifficile #Infection ... #Pharmacology # ... Clostridium #Table #Comparison
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... infection Episode ... #Pharmacology ... #Clostridium #CDifficile ... IDSA2017 #Adjunct #Antibiotics
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... if MIC<0.12 ug/ml ... Enteric #Bacterial #IDSA ... Treatment #management #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... 100 cells/mm3 g/mL ... Penicilliosis #IDSA ... Treatment #management #opportunistic ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... suspension 4–6 mL ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... , 2 doses (0.5 mL ... #Zoster #VZV #IDSA ... Treatment #management #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... Castleman’s Disease (MCD ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology